unknown
Stage
About
Gyala Therapeutics is developing GYA01, a CAR-T cell therapy for hematologic cancers including acute myeloid leukemia (AML) and T-cell acute lymphoblastic leukemia (T-ALL), and is currently conducting Phase I/IIa clinical trials.
Explore Gyala Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.